Syntekabio will unveil its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the UKC 2022 in Arlington, VA, on August 19. The platforms are set to launch in September and aim to enhance drug discovery efficiency. Kilyoung Kim, PhD, will represent the company at the symposium, fostering U.S.-Korea cooperation in biotechnology.
Syntekabio, a leading global AI drug discovery and development firm, will showcase its advanced AI-driven drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) 2022, taking place on August 19, 2022, in Arlington, Virginia. These proprietary cloud platforms, set to launch in September, signify a significant advancement in the biotechnology sector, aimed at accelerating drug discovery processes.
The UKC is designed for professionals in science, engineering, technology, and entrepreneurship from both the United States and Korea, facilitating collaboration and networking opportunities. The Innovative and Entrepreneurship Symposium (IES) will feature presentations from participating companies with promising innovations, highlighting avenues for cross-border business growth. Kilyoung Kim, PhD, Chief Scientific Officer and President of Syntekabio USA, will introduce the firm and discuss its latest technological advancements during the event.
Scheduled for publication in September, DeepMatcher® and NEO-ARS™ are anticipated to contribute substantially to the efficiency of drug discovery, leveraging artificial intelligence to drive innovation in the pharmaceutical industry. Following the presentation, Syntekabio leadership will be available for media discussions, providing further insight into their cutting-edge initiatives.
Syntekabio’s presence at the UKC 2022 underscores its commitment to fostering international partnerships and advancing healthcare solutions through innovative technology.
Syntekabio, established in 2009 and headquartered in South Korea, specializes in AI and big data-driven drug discovery solutions. The company is focused on creating transformative medicines compliant with international standards, thereby enhancing patient care globally. The forthcoming release of DeepMatcher® and NEO-ARS™ aligns with current trends in biotechnology, where the integration of artificial intelligence is crucial for expedited and effective drug development. The UKC serves as an important platform for fostering collaboration between U.S. and Korean professionals, which is essential for addressing contemporary healthcare challenges.
In summary, Syntekabio’s presentation at the UKC 2022 represents a pivotal moment in the field of AI-driven drug discovery. The introduction of DeepMatcher® and NEO-ARS™ is expected to revolutionize the pharmaceutical landscape by enhancing the speed and efficacy of drug development. This initiative not only highlights Syntekabio’s innovative approach but also emphasizes the importance of international collaboration in advancing healthcare solutions.
Original Source: www.globenewswire.com
